AR115949A1 - Compuestos heterocíclicos - Google Patents
Compuestos heterocíclicosInfo
- Publication number
- AR115949A1 AR115949A1 ARP190102302A ARP190102302A AR115949A1 AR 115949 A1 AR115949 A1 AR 115949A1 AR P190102302 A ARP190102302 A AR P190102302A AR P190102302 A ARP190102302 A AR P190102302A AR 115949 A1 AR115949 A1 AR 115949A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocyclic compounds
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: X es C-R³; m es 0 ó 1; n se selecciona entre 0, 1 y 2; y L se selecciona entre -C&
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18188679 | 2018-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115949A1 true AR115949A1 (es) | 2021-03-17 |
Family
ID=63244466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102302A AR115949A1 (es) | 2018-08-13 | 2019-08-13 | Compuestos heterocíclicos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20210277020A1 (es) |
| EP (1) | EP3837264A1 (es) |
| JP (1) | JP2021533093A (es) |
| KR (1) | KR20210044217A (es) |
| CN (1) | CN112469724A (es) |
| AR (1) | AR115949A1 (es) |
| AU (1) | AU2019322161A1 (es) |
| BR (1) | BR112020025642A2 (es) |
| CA (1) | CA3098272A1 (es) |
| CL (1) | CL2021000361A1 (es) |
| CR (1) | CR20210056A (es) |
| IL (1) | IL280762A (es) |
| MA (1) | MA53220A (es) |
| MX (1) | MX2020013719A (es) |
| PE (1) | PE20211380A1 (es) |
| PH (1) | PH12021500015A1 (es) |
| SG (1) | SG11202012222TA (es) |
| TW (1) | TWI814882B (es) |
| WO (1) | WO2020035425A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| TW201936602A (zh) | 2017-11-28 | 2019-09-16 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| MX2020008949A (es) | 2018-02-27 | 2021-01-08 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. |
| JP7391046B2 (ja) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体 |
| IL279829B2 (en) | 2018-07-05 | 2025-05-01 | Incyte Holdings Corp | Fused pyrazine derivatives as A2A/A2B inhibitors |
| JP7637049B2 (ja) | 2018-08-13 | 2025-02-27 | エフ． ホフマン－ラ ロシュ アーゲー | モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| CN114650994A (zh) * | 2019-09-12 | 2022-06-21 | 豪夫迈·罗氏有限公司 | 放射性标记的化合物 |
| CA3151516A1 (en) | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| JP2022549810A (ja) * | 2019-09-23 | 2022-11-29 | エフ．ホフマン－ラ ロシュ アーゲー | 複素環化合物 |
| EP4034541A1 (en) * | 2019-09-24 | 2022-08-03 | F. Hoffmann-La Roche AG | Heterocyclic compounds |
| CN114401968A (zh) * | 2019-09-24 | 2022-04-26 | 豪夫迈·罗氏有限公司 | 新颖杂环单酰基甘油脂肪酶(magl)抑制剂 |
| AU2021338497A1 (en) | 2020-09-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Heterocyclic compounds |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| CN119731180A (zh) | 2022-08-05 | 2025-03-28 | 金橘生物科技公司 | 杂环化合物及其用途 |
| EP4665718A1 (en) | 2023-02-13 | 2025-12-24 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| FR2915197B1 (fr) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| CN102596962A (zh) | 2009-09-10 | 2012-07-18 | 弗·哈夫曼-拉罗切有限公司 | Jak抑制剂 |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US9029368B2 (en) * | 2011-11-30 | 2015-05-12 | Actelion Pharmaceuticals Ltd. | 3,7-disubstituted octahydro-2H-pyrido[4,3-E][1,3]oxazin-2-one antibiotics |
| WO2016158956A1 (ja) * | 2015-03-30 | 2016-10-06 | 武田薬品工業株式会社 | 複素環化合物 |
| ES2945314T3 (es) | 2015-05-21 | 2023-06-30 | Glaxosmithkline Ip Dev Ltd | Derivados de benzoimidazol como inhibidores de PAD4 |
| EP3438109B1 (en) * | 2016-03-31 | 2021-08-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| TWI738753B (zh) * | 2016-03-31 | 2021-09-11 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
-
2019
- 2019-08-12 AU AU2019322161A patent/AU2019322161A1/en not_active Abandoned
- 2019-08-12 KR KR1020217004224A patent/KR20210044217A/ko not_active Ceased
- 2019-08-12 PE PE2020002021A patent/PE20211380A1/es unknown
- 2019-08-12 MA MA053220A patent/MA53220A/fr unknown
- 2019-08-12 JP JP2021503816A patent/JP2021533093A/ja active Pending
- 2019-08-12 BR BR112020025642-0A patent/BR112020025642A2/pt not_active IP Right Cessation
- 2019-08-12 CA CA3098272A patent/CA3098272A1/en active Pending
- 2019-08-12 CR CR20210056A patent/CR20210056A/es unknown
- 2019-08-12 WO PCT/EP2019/071522 patent/WO2020035425A1/en not_active Ceased
- 2019-08-12 CN CN201980048654.2A patent/CN112469724A/zh active Pending
- 2019-08-12 EP EP19755856.2A patent/EP3837264A1/en not_active Withdrawn
- 2019-08-12 MX MX2020013719A patent/MX2020013719A/es unknown
- 2019-08-12 SG SG11202012222TA patent/SG11202012222TA/en unknown
- 2019-08-13 TW TW108128684A patent/TWI814882B/zh not_active IP Right Cessation
- 2019-08-13 AR ARP190102302A patent/AR115949A1/es not_active Application Discontinuation
-
2021
- 2021-02-09 IL IL280762A patent/IL280762A/en unknown
- 2021-02-10 CL CL2021000361A patent/CL2021000361A1/es unknown
- 2021-02-11 US US17/174,000 patent/US20210277020A1/en not_active Abandoned
- 2021-02-11 PH PH12021500015A patent/PH12021500015A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20211380A1 (es) | 2021-07-27 |
| BR112020025642A2 (pt) | 2021-03-23 |
| MA53220A (fr) | 2021-11-17 |
| TWI814882B (zh) | 2023-09-11 |
| SG11202012222TA (en) | 2021-01-28 |
| CR20210056A (es) | 2021-03-02 |
| CA3098272A1 (en) | 2020-02-20 |
| JP2021533093A (ja) | 2021-12-02 |
| PH12021500015A1 (en) | 2021-09-13 |
| TW202035421A (zh) | 2020-10-01 |
| CL2021000361A1 (es) | 2021-07-09 |
| IL280762A (en) | 2021-04-29 |
| MX2020013719A (es) | 2021-03-02 |
| CN112469724A (zh) | 2021-03-09 |
| EP3837264A1 (en) | 2021-06-23 |
| WO2020035425A1 (en) | 2020-02-20 |
| KR20210044217A (ko) | 2021-04-22 |
| AU2019322161A1 (en) | 2020-11-12 |
| US20210277020A1 (en) | 2021-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115949A1 (es) | Compuestos heterocíclicos | |
| PE20221339A1 (es) | Inhibidores de parp1 | |
| MX2022011283A (es) | Compuestos pirimidoheterocíclicos y aplicación de los mismos. | |
| CL2020003219A1 (es) | Compuestos | |
| AR108711A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| CO2021000078A2 (es) | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2) | |
| CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
| AR117920A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| AR120029A1 (es) | Compuestos heterocíclicos | |
| AR119672A1 (es) | Inhibidor de 15-pgdh | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| CO2023000396A2 (es) | Nuevo inhibidor de la secreción de ácido y uso del mismo | |
| EA202191991A1 (ru) | Новые производные гетеротрициклического соединения и их применение | |
| PE20212070A1 (es) | Moduladores de trex1 | |
| CO2022004305A2 (es) | Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3 | |
| AR111806A1 (es) | Derivados de indol n-sustituidos | |
| MX2024003130A (es) | Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma. | |
| AR112333A1 (es) | Pirrolopirimidina y derivados de pirrolopirimidina | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| CL2023000313A1 (es) | Forma sólida de un compuesto | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
| EA202090653A1 (ru) | Циклоолефиновые замещённые гетероароматические соединения и их применение | |
| MX2023015440A (es) | Compuesto de sulfoximina y uso del mismo. | |
| AR110770A1 (es) | Moduladores del canal de potasio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |